go-v.orgdoi

Active Chronic Hepatitis B increases the risk of Colorectal Liver Metastasis - A retrospective cross-sectional study

Yue Yang, Lijie Song, Jingyu Cao, Jing Liu, Dongxu Wang, Linda L. Wong, Lei Zhao · Journal of Cancer · 2021

  • DOI 10.7150/jca.51233
  • Publisher Ivyspring International Publisher
  • Type article
  • Issued 2021

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Journal of Cancer · Ivyspring International Publisher · article · 2021

Abstract

Background: A considerable part of colorectal cancer (CRC) patients also have chronic hepatitis B (CHB), esp. in Asia.The effect of concomitant active CHB on the hazard of colorectal liver metastasis (CRLM) remains unclear.To evaluate the effect of concomitant active CHB on the risk of CRLM.Methods: The medical record of all newly diagnosed CRC patients who were hospitalized to the three hospitals between January 2010 to January 2016 were reviewed, the prevalence of synchronous CRLM (synCRLM) were retrospectively studied.Totally 7187 cases of newly diagnosed CRC, including 368 cases with concomitant CHB were recruited.The prevalence of synCRLM in HBsAg + /HBeAg + patients was compared to that in HBsAg + /HBeAg -patients.Significant risk factors for synCRLM were analyzed by logistic regression analysis.Results: The overall prevalence of synCRLM was 8.72% (627/7187) and was significantly higher in HBsAg+ patients (43/368) than HBsAg-patients (576/6742) (11.68% vs.

8.54%, P=0.037; χ 2 test).In 368 HBsAg + patients, 365 patients also had HBeAg information.synCRLM was also more prevalent inHBsAg + /HBeAg + patients (13/69) compared to HBsAg + /HBeAg -patients (30/296) (18.84% vs. 10.14%,P=0.043; χ 2 test).In univariate and multivariate logistic regression analysis, HBeAg positivity was the second strongest predictor of synCRLM (multivariate: OR, 2.622, P=0.020) after CEA.(univariate: OR, 2.920, P=0.001).Conclusions: HBeAg positivity is a clinical risk factor for CRLM that can be readily identified and addressed.Whether anti-CHB treatment can decrease the risk of CRLM worth carefully-designed prospective trials to define.

Open the resolved locator · 10.7150/jca.51233

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-19 21:07 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://www.jcancer.org/v12p1398.htm
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.